← Leaderboards
Kalpna Gupta
University Of Minnesota Twin Cities
$21,163,908
Attributed
$26,280,327
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,280,327 · 9
By mechanism
R01$14,432,223 · 6
U01$9,579,537 · 1
U24$1,893,837 · 1
T35$374,730 · 1
Top collaborators
- Donald A Simone12 shared
- Daniela Annenelie Bota11 shared
- Connie Meeyoung Rhee4 shared
- Claudia Michelle Campbell2 shared
- Wally R Smith2 shared
- Kamyar Kalantar-Zadeh1 shared
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainTransgenic OrganismsSickle Cell AnemiaPreventSkinNeuronsSicklingAttenuatedHyperalgesiaCellsChronicLeadOpioidInflammationMultidisciplinarySignal PathwayIn VitroIn VivoDoseBlood VesselsQuality Of LifeAbsence Of Pain SensationInjuryBehavioral
Grant awards (65)
Sickle Cell Disease Pain Analgesia And Integrative Network$929,890
U24 · FY2025 · AT · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$601,825
R01 · FY2025 · CA
Summer Mentoring and Research Training (SMART)$90,553
T35 · FY2025 · DK · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$82,514
R01 · FY2025 · CA
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$80,303
R01 · FY2025 · CA
Sickle Cell Disease Pain Analgesia And Integrative Network$963,947
U24 · FY2024 · AT · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$574,826
R01 · FY2024 · CA
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$95,469
R01 · FY2024 · CA
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$82,514
R01 · FY2024 · CA
Summer Mentoring and Research Training (SMART)$79,969
T35 · FY2024 · DK · contact PI
Supplement to Promote Diversity: Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$33,139
R01 · FY2024 · CA
Supplement to Promote Diversity:Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$18,319
R01 · FY2024 · CA
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$613,079
R01 · FY2023 · CA
Summer Mentoring and Research Training (SMART)$72,906
T35 · FY2023 · DK · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$693,748
R01 · FY2022 · HL · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$616,655
R01 · FY2022 · CA
Role of mast cell traps in Alzheimer's disease$390,574
R01 · FY2022 · HL · contact PI
Summer Mentoring and Research Training (SMART)$66,424
T35 · FY2022 · DK · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$708,753
R01 · FY2021 · HL · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$634,722
R01 · FY2021 · CA
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$87,455
R01 · FY2021 · HL · contact PI
Summer Mentoring and Research Training (SMART)$64,878
T35 · FY2021 · DK · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$608,896
R01 · FY2020 · HL · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$154,315
R01 · FY2020 · HL · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$69,168
R01 · FY2020 · HL · contact PI
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease$637,263
R01 · FY2019 · HL · contact PI
Cannabinoid Modulation of Hyperalgesia$488,499
R01 · FY2019 · HL
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$500,000
U01 · FY2018 · HL · contact PI
Cannabinoid Modulation of Hyperalgesia$488,499
R01 · FY2018 · HL
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$1,844,665
U01 · FY2017 · HL · contact PI
Cannabinoid Modulation of Hyperalgesia$489,124
R01 · FY2017 · HL
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$66,586
U01 · FY2017 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$1,869,191
U01 · FY2016 · HL · contact PI
Cannabinoid Modulation of Hyperalgesia$493,069
R01 · FY2016 · HL
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$100,000
U01 · FY2016 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$25,682
U01 · FY2016 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$1,848,808
U01 · FY2015 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$8,650
U01 · FY2015 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$1,855,301
U01 · FY2014 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$21,634
R01 · FY2014 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$8,238
R01 · FY2014 · HL · contact PI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease$1,460,654
U01 · FY2013 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$430,237
R01 · FY2013 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$22,428
R01 · FY2013 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$492,012
R01 · FY2012 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$44,162
R01 · FY2012 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$492,751
R01 · FY2011 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$448,453
R01 · FY2011 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$26,686
R01 · FY2011 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$14,756
R01 · FY2011 · HL · contact PI
Characteristics and mechanisms of pain in sickle cell disease$458,380
R01 · FY2010 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$413,000
R01 · FY2010 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$26,153
R01 · FY2010 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$8,390
R01 · FY2010 · HL · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$378,500
R01 · FY2009 · HL · contact PI
Opioid and Breast Cancer Growth and Metastasis$223,970
R01 · FY2009 · CA · contact PI
Opioid Activity in Endothelium in Sickle Cell Disease$391,250
R01 · FY2008 · HL · contact PI
Opioid and Breast Cancer Growth and Metastasis$223,970
R01 · FY2008 · CA · contact PI
Opioid and Breast Cancer Growth and Metastasis$216,555
R01 · FY2007 · CA · contact PI
Opioid and Breast Cancer Growth and Metastasis$224,931
R01 · FY2006 · CA · contact PI
Opioid and Breast Cancer Growth and Metastasis$236,210
R01 · FY2005 · CA
Opioid Activity in Endothelium in Sickle Cell Disease$222,750
R01 · FY2005 · HL
Opioid Activity in Endothelium in Sickle Cell Disease$222,750
R01 · FY2004 · HL
Opioid Activity in Endothelium in Sickle Cell Disease$222,750
R01 · FY2003 · HL
Opioid Activity in Endothelium in Sickle Cell Disease$218,579
R01 · FY2002 · HL